SCHEMBL3708633

SCHEMBL3708633

Cn1ncc2cc(Nc3nc(N4CCC(CN)CC4)c4occc4n3)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 1/20 0.40
EGFR P00533 2/20 0.37
ERBB2 P04626 1/20 0.37
SYK P43405 9/20 0.37
KDR P35968 2/20 0.37
JAK2 O60674 2/20 0.37
ABL1 P00519 2/20 0.37
LCK P06239 2/20 0.37
FYN P06241 2/20 0.37
RET P07949 2/20 0.37
TTK P33981 2/20 0.37
MAPK8 P45983 2/20 0.37
TNK2 Q07912 2/20 0.37
MAP4K2 Q12851 2/20 0.37
DAPK3 O43293 1/20 0.37
STK16 O75716 1/20 0.37
MAP4K4 O95819 1/20 0.37
PAK4 O96013 1/20 0.37
LTK P29376 1/20 0.37
GRK5 P34947 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3705447 0.91 CDC7 (0.38) CDC7EGFRERBB2SYKKDR
SCHEMBL3712741 0.88 TBK1 (0.39) CDC7EGFRERBB2SYKKDR
SCHEMBL3700643 0.87 SYK (0.37) CDC7EGFRERBB2SYKKDR
SCHEMBL3705694 0.85 TBK1 (0.37) CDC7EGFRSYKKDRJAK2
SCHEMBL3712744 0.82 SYK (0.37) CDC7EGFRSYKKDRTGFBR1
SCHEMBL3703811 0.80 SYK (0.54) CDC7EGFRSYKKDRJAK2
SCHEMBL3716964 0.79 SYK (0.59) CDC7SYKKDRJAK2ABL1
SCHEMBL1709894 0.79 SYK (0.41) CDC7EGFRSYKKDRJAK2
SCHEMBL3712696 0.78 TRPV1 (0.40) EGFRSYKKDRJAK2ABL1
SCHEMBL1709785 0.78 SYK (0.47) SYKKDRJAK2ABL1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US claimed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US claimed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS CDK2, DPYD, CDK3 CDC7 289/4885EGFR 1238/4885ERBB2 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.